Clinical trials: Hypoglycaemia
Diabetes Mellitus, Type II, Hypoglycemia
Effects of Mild Hypoglycaemia on Cognitive Function in Type 2 Diabetes
Hypoglycaemia in subjects suffering from type 2 diabetes may have substantial consequences including a significant negative impact on quality of life.
- Conditions
- Diabetes Mellitus, Type II, Hypoglycemia, Cognitive Change
- Trial name
- NCT03014011
- Testing
- Hypoglycaemic clamp, Euglycaemic clamp
- Where
- Denmark
- Volunteers
- 28 people
- Sponsor
- Bispebjerg Hospital
Type 1 Diabetes
Clinical Assessment of a Closed-loop System With Glucagon, Exercise and Mixed Meals
The diabetes technology group at Imperial College have developed a bio-inspired artificial pancreas (BiAP) system which uses a control algorithm based on a mathematical model of beta-cell physiology.
- Trial name
- NCT02397265
- Testing
- Bi-hormonal closed loop pump, Standard opened loop pump, Insulin closed loop
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Imperial College London
Postbariatric Hypoglycemia
Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects
This clinical study will examine the safety and tolerability, as well as the effects of orally administered mizagliflozin on post prandial glucose and insulin levels in subjects diagnosed with post-bariatric hypoglycemia (PBH).
- Trial name
- NCT05541939
- Testing
- Mizagliflozin
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Vogenx, Inc.
Hyperparathyroidism, Hypercalcemia
Studies of Elevated Parathyroid Activity
Observational Phase: Patients whose parathyroid activity is elevated above normal are referred to as having hyperparathyroidism.
- Conditions
- Hyperparathyroidism, Hypercalcemia, Parathyroid Neoplasm, Multiple Endocrine Neoplasia
- Trial name
- NCT00001277
- Testing
- 68Ga-Dotatate, 18F-DOPA
- Where
- United States
- Volunteers
- 1,553 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type1diabetes, Hypoglycemia
Adrenergic System in Islet Transplantation
To determine the effect of sympathetic neural and hormonal (epinephrine) input on islet cell hormonal responses to insulin-induced hypoglycemia in type 1 diabetic recipients of intrahepatic islet transplantation.
- Conditions
- Type1diabetes, Hypoglycemia, Hypoglycemia Unawareness, Islet Cell Transplantation
- Trial name
- NCT03079921
- Testing
- Phentolamine, Propranolol
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Pennsylvania
Hypoglycemia, Diabetes Mellitus, Type 1
A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus
The trial's objective is to evaluate the immunogenicity of repeated single doses of dasiglucagon* and GlucaGen following subcutaneous (SC) administration in patients with type 1 diabetes mellitus (T1DM) and further to evaluate…
- Trial name
- NCT03216226
- Testing
- dasiglucagon, GlucaGen
- Where
- 7 sites in United States, Austria and 2 more
- Volunteers
- 112 people
- Sponsor
- Zealand Pharma
Type 2 Diabetes, Hypoglycemia
Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride
The purpose of this study was to compare the effect of a fixed dose combination of vildagliptin plus metformin versus combination therapy of glimepiride plus metformin in glycemic variability in patients with type 2 diabetes who…
- Trial name
- GLOBE (NCT02007278)
- Testing
- vildagliptin and metformin (combination), glimepiride, Metformin
- Where
- 8 sites in Colombia
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Type 1 Diabetes Mellitus, Hypoglycemia
Allogeneic Islet Cells Transplanted Onto the Omentum
Current islet transplantation into the portal vein of the liver has shown the unique ability of islets to stabilize blood glucose levels and prevent severe hypoglycemia in a selected group of subjects with Type 1 diabetes.
- Conditions
- Type 1 Diabetes Mellitus, Hypoglycemia, Hypoglycemia Unawareness
- Trial name
- NCT02213003
- Testing
- Islet transplantation
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Rodolfo Alejandro
Hypoglycemia
PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients
The purpose of the study is to assess the safety, speed of absorption, and onset of action of G-Pump™ (glucagon infusion) at three subcutaneous doses as compared to Novo GlucaGen®, all delivered via an OmniPod® infusion pump to…
- Trial name
- NCT02081001
- Testing
- Novo Nordisk GlucaGen®, G-Pump™ (glucagon infusion)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Xeris Pharmaceuticals
Type 1 Diabetes Mellitus
Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D)
A multi-center, randomized, crossover trial consisting of three sequential 12-week periods, with the HCL feature used during one period, the PLGS feature used during one period and SAP therapy (control) during one period.
- Trial name
- AIDE T1D (NCT04016662)
- Testing
- Tandem t:slim X2 with HCL or PLGS
- Where
- 4 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Jaeb Center for Health Research
Type 2 Diabetes Mellitus, Colonoscopy
Abnormal Blood Sugar Tests in Diabetic Patients During Colonoscopy Preparation
Type 2 diabetes is rapidly increasing globally and has been associated with an increased risk of colorectal cancer. Therefore, the numbers of diabetic patients who will undergo colonoscopic screening are expected to grow…
- Trial name
- NCT03109951
- Testing
- Colonoscopy preparation using polyethylene glycol
- Where
- South Korea
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- Catholic Kwandong University
Hypoglycemia Unawareness, Diabetes Mellitus, Type 1
Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses
This is a prospective, randomized, controlled, double-blind, parallel 4-group trial with the primary analysis after 4 weeks of treatment with continuous subcutaneous glucagon infusion (CSGI) or placebo.
- Trial name
- NCT03490942
- Testing
- Glucagon
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Xeris Pharmaceuticals
Hypoglycemia, Cognitive Impairment
The Impact of Renin-angiotensin System on Brain Activation During Hypoglycaemia in Healthy Men, a PET Study
The purpose of this study is to evaluate the cerebral blood flow in subjects with high and low activity in the renin-angiotensin system (RAS).The renin-angiotensin system is a hormone system which is involved in the regulation of…
- Trial name
- NCT00264641
- Testing
- Human insulin
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Hypoglycaemia Research Group
Diabetes Mellitus, Type 1
A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes
This study has 2 parts. Each participant will receive a daily injection of LY2605541 during one treatment period and a daily injection of insulin glargine during one treatment period.
- Trial name
- NCT01769404
- Testing
- LY2605541, Insulin Glargine
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Eli Lilly and Company
Hypoglycemia, Type 2 Diabetes
Hypoglycemia (Low Blood Sugar) and the Heart
The risk of hypoglycemia (low blood sugar) associated with the treatment of diabetes increases with age. Hypoglycemia is a common reason for admission to hospital for older patients with diabetes.
- Trial name
- NCT01980914
- Testing
- iPro2 glucose sensor attachment
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- University of British Columbia
Hypoglycemia
Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia
The purpose of this study is to demonstrate that G-Pen(TM) glucagon is comparable to Lilly Glucagon(TM) in terms of safety and efficacy, as a treatment for severe hypoglycemia, a complication of diabetes.
- Trial name
- NCT01972152
- Testing
- G-Pen(TM) 1 mg, Lilly Glucagon(TM) 1 mg, G-Pen(TM) 0.5 mg
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Xeris Pharmaceuticals
Congenital Hyperinsulinism
CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism
This is a Phase 2, multi-center, randomized, placebo-controlled, double-blind trial with open-label follow-up designed to assess the efficacy of Xeris Glucagon delivered as a continuous subcutaneous infusion to prevent…
- Trial name
- NCT02937558
- Testing
- Glucagon
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Xeris Pharmaceuticals
Type1 Diabetes Mellitus
Mechanisms for Restoration of Hypoglycemia Awareness
To assess if using the hypoglycemic clamp and functional magnetic resonance imaging (fMRI) scanning in hypoglycemia unaware and aware T1DM patients and healthy controls have showed distinct differences in patterns of brain…
- Trial name
- NCT03738852
- Testing
- Continuous Glucose Monitor (CGM), Insulin
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Yale University
Diabetes Mellitus, Type 2
Time in Glucose Hospital Target
Inpatient management of glycemia in people with diabetes has been inadequately studied. Previous randomized trials of intensive insulin therapy in the hospital setting resulted in excessive hypoglycemia.
- Trial name
- TIGHT (NCT05135676)
- Testing
- Blinded CGM, real-time CGM
- Where
- 6 sites in United States
- Volunteers
- 166 people
- Sponsor
- Jaeb Center for Health Research
Hypoglycemia
Glucagon Ready-to-Use (RTU) for Prevention of Exercise-Induced Hypoglycemia During Aerobic Exercise in Adults With T1D
This study is a randomized, placebo-controlled, double-blind, 2-treatment, 2-period, crossover comparison in a clinical research center (CRC) setting, followed by a randomized, placebo-controlled, double-blinded, 2-arm parallel…
- Trial name
- NCT03841526
- Testing
- Glucagon RTU Injection With Insulin Pump Reduction, Vehicle for Glucagon RTU Injection With Insulin Pump Reduction, Glugaon RTU Injection Without Insulin Pump Reduction
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- Xeris Pharmaceuticals